anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses traditional Chinese medicine sitting lotion for treating treating chronic prostatitis. The traditional Chinese medicine sitting lotion is prepared by adding proper amount of water into the traditional Chinese raw materials including securidaca inappendiculata hassk, amur barberry root and branchlet, nervos brake herb, Guangdong lysimachia christinae hance, dianthus superbus, ligusticum wallichii, rhizoma anemarrhenae, curcuma zedoary, cassia twig, divaricate knotweed root and cynomorium songaricum, and decocting the mixture. The traditional Chinese medicine sitting lotion is used by decocting the medicines to obtain decoction, using hot steam to fume the affected part, using the lotion to the wash the local part after the temperature drops. The traditional Chinese medicine sitting lotion acts on an organism through the effect of skin mucosa by aid of drug effect and heating power, can promote the grain of the skin and the texture of the subcutaneous flesh to be dredged, and enables veins to be mediated and qi and blood to be smooth, and the medicines can be absorbed fast after fuming and washing. The traditional Chinese medicine sitting lotion can regulate qi, blood, yin and yang of the body, strengthens the body resistance and eliminates pathogenic factors, and accordingly the aim of treating is achieved. According to clinical experiment of the hospital, the curing rate and total effective rate can respectively reach 66.7% and 97.1%, and the traditional Chinese medicine sitting lotion is remarkable in curing effect, simple in method and free of side and toxic effect.
Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
PURPOSE:To enable quick measurement of the value of a neutral antibody against microorganisms to be performed, by using a labelled complement together with the microorganism. CONSTITUTION:A body liquor or the like of a patient is used in the measure ment as microorganism and the labelled complement herein used is preferably a bond matter in which various labels are coupled to a part other than that having a bonding activity to emmunoglobulin of a complement C1q component. It is desired that the S-S bond is first severed by a reducing agent to make a reducing C1q with as SH group at this part exposed, then, a material into which an active group is introduced to react with the SH group is produced and finally, it is made to react with the reducing C1q to obtain a bond of the C1q and the material. In the measurement of a neutral antibody, first, a virus liquid with the known amount of virus is made to react with a body liquor to be inspected and the virus left is vaccinated to a host cell cultured on a microplate in a single layer to adsorb. Subsequently, the single layer of cell is washed and the virus is proliferated. Then, within 24hr of cultivation, endogeous enzyme and virus are inactivated by methanol containing hydrogen peroxide or the like.
The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
Patients and clinical features. The study will be carried out at National Taiwan University hospital, a tertiary medical center in Taipei. The Medical Genetics Department at National Taiwan University Hospital receives referral and conducts genetic testing for hospitals all around Taiwan. We will review the medical chart of all patients with documented mitochondrial DNA nt3243 point mutation. Demographic data, age at onset of symptoms, clinical features (including stroke, seizure-like episode, lactic level, diabetes mellitus, hearing impairment, myopathy, electrocardiogram abnormality, chronic progressive external ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full MELAS phenotype was defined as the presence of focal central nervous system events, either seizures, strokes, or both.

Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase chain reaction (PCR) for mitochondrial DNA nt3243 point mutation was carried out by left primer 5'-cggagtaatccaggtcggtt-3' and right primer 5'-ggaattgaacctctgactgt-3'. Presence of mitochondrial DNA nt3243 A\>G mutation was detected after Hae III restriction enzyme digestion.

Heteroplasmy of mitochondrial nt3243A\>G mutation was detected by real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay as previously reported \[19\]. In brief, wild-type and mutant-target primers, each 500 nM, were added into a 10-ml PCR reaction containing 1X KAPA SYBR® FAST ABI Prism® qPCR Master Mix (KAPABIOSYSTEMS, Cat No. KK4603) and 4 ng of genomic DNA. Real-time PCR conditions were 2 min at 50°C, 20 seconds at 95°C, followed by 40 cycles of 15 seconds of denaturation at 95°C and 30 seconds of annealing/extension at 62°C. Data of cross point and concentration fluorescent signal intensity of PCR products was recorded and analyzed by ABI StepOnePlusTM Real-Time PCR System (Applied Biosystems) and StepOne software v2.1 (Applied Biosystems). The threshold cycle ( CT value) within the linear exponential phase was used to construct the standard curve and to measure the original copy number of DNA template. The percentage of the mutant mtDNA was calculated using formula as below: Heteroplasmy %= 1/(1+ 1/2△CT).

Statistical analysis. SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Results were given as median and range, or mean ± 1 SD, when appropriate. Student 's t-test was used to compare unpaired groups. Fisher's exact test was used to determine associations between two categorical variables. Cox-regression model was used to analyze possible prognostic factors. Inter-group differences at outcome were compared by Kaplan-Meier estimate and log-rank test. Pearson's correlation was used to correlate heteroplasmy to age of diagnosis. A p value \< 0.05 was considered statistically significant.
Important progress has been made toward unravelling the complex genetics underlying atrial fibrillation (AF). Initial studies were aimed to identify monogenic causes; however, it has become increasingly clear that the most common predisposing genetic substrate for AF is polygenic. Despite intensive investigations, there is robust evidence for rare variants for only a limited number of genes and cases. Although the current yield for genetic testing in early onset AF might be modest, there is an increasing appreciation that genetic culprits for potentially life-threatening ventricular cardiomyopathies and channelopathies might initially present with AF. The potential clinical significance of this recognition is highlighted by evidence that suggests that identification of a pathogenic or likely pathogenic rare variant in a patient with early onset AF is associated with an increased risk of death. These findings suggest that it might be warranted to screen patients with early onset AF for these potentially more sinister cardiac conditions. Beyond facilitating the early identification of genetic culprits associated with potentially malignant phenotypes, insight into underlying AF genetic substrates might improve the selection of patients for existing therapies and guide the development of novel ones. Herein, we review the evidence that links genetic factors to AF, then discuss an approach to using genetic testing for early onset AF patients in the present context, and finally consider the potential value of genetic testing in the foreseeable future. Although further work might be necessary before recommending uniform integration of genetic testing in cases of early onset AF, ongoing research increasingly highlights its potential contributions to clinical care.
This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook.
Firstly Dose Escalation and Dose Expansion of HRS-8080 monotherapy should be conducted. After RP2D and MTD of the HRS-8080 monotherapy were confirmed, Dose Escalation and Dose Extension of HRS-8080 in combination with other anti-cancer treatment would be completed, including SHR 6390, or Abemaciclib, or Everolimus.
Since the metabolism of methadone is mediated primarily by CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of methadone. The expected clinical results would be increased or prolonged opioid effects. Thus, methadone-treated patients coadministered strong inhibitors of CYP3A4, such as azole antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), with methadone should be carefully monitored and dosage adjustment should be undertaken if warranted. Some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) may increase methadone plasma levels upon coadministration with methadone and result in increased opiate effects and/or toxicity.

Voriconazole – Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed.
PURPOSE:To efficiently separate and purify a biomembrane without deforming spherical particles even under pressure, by passing a solution containing the biomembrane through a column packed with spherical particles of crosslinked glucomannan. CONSTITUTION:Glucomannan is swollen with formamide, treated with acetic acid, etc., in the presence of an esterifying catalyst to give a glucomannan ester, which is dissolved in a solvent such as dichloromethane. In the operation, a simultaneous addition of 100-500wt.% based on the glucomannan of a diluent (e.g. THF) can provide a gel having >=1,000,000 exclusion limit mol.wt. Then the solution is stirred in an aqueous medium to give spherical particles having 1-500mum particle diameter. The particles are packed into a column, a solution containing a biomembrane (e.g. natural liposome, synthetic bimolecular membrane or multi-layer liposome) is passed through the column and separated.
Digital tomosynthesis is a form of limited angle tomography that creates a series of section images using a conventional x-ray tube and generator, a digital detector, and appropriate reconstruction software. It creates section images from a series of projection images acquired as the x-ray tube moves along a prescribed path. Because tomosynthesis can minimize the visual presence of overlying anatomy - the ribs, for example - it has the potential to improve the detection of lesions such as pulmonary nodules when compared with conventional chest radiography.

The primary aim of this study is to determine whether the use of VolumeRAD tomosynthesis, in addition to CxR, increases physician accuracy in the detection of lung nodules between 3mm and 20mm in diameter when compared to conventional posterior-anterior (PA) and lateral (LAT) chest radiography (CxR). This aim will be addressed by measuring free-response performance of experienced (with VolumeRAD), blinded expert readers' detection performance. Specifically, we will compare detection performance, as measured by the area under the alternative free response receiver operating characteristic (AFROC) curve, among readers viewing PA and LAT chest X-rays versus VolumeRAD tomosynthesis. The nodule will be the unit of analysis.
Technologies for attestation techniques, systems, and methods are provided for determining patient movement and conditions. The patient's movement may be determined by passive indoor positioning technology using channel state information (CSI). Activity data from an activity database may be retrieved from a Wi-Fi access point located in proximity to a monitored space and analyzed to determine an activity trend of a patient in the monitored space. A electronic medical records database may be polled for one or more health events each associated with a set of health parameters. The activity data may be compared to the associated parameter sets of the health events to identify any matches. A notification may be sent to a designated device (e.g., of a caregiver) based on a match between the activity data or trends thereof with the parameter set of a health event,
Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
Ripretinib is a kinase inhibitor. The chemical name of ripretinib is 1-(4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl)-3-phenylurea. The molecular formula is C24H21BrFN5O2 and the molecular weight is 510.36 g/mol. The chemical structure of ripretinib is shown below: 

Ripretinib is a white to off-white crystalline solid. Ripretinib is a lipophilic, weak base, and practically insoluble in aqueous media. 

QINLOCK is available as a white to off-white, oval tablets for oral use containing 50 mg of ripretinib. The tablet is debossed with “DC1” on one side. Each tablet contains the following inactive ingredients: crospovidone, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide.
The invention provides radix notoginseng, radix astragali and lycii fructus wine and a preparation method thereof. The radix notoginseng, radix astragali and lycii fructus wine is prepared from a raw material comprising a healthcare composition and Baijiu, wherein the healthcare composition comprises radix notoginseng, radix astragali and lycii fructus in parts by weight; and a mass ratio of radix notoginseng to radix astragali to lycii fructus is controlled to be 1:1:0.6 to 0.8. The preparation method comprises: extracting the healthcare composition for multiple times, merging the extract liquid obtained in multiple times, cold storing the merged extract liquid, standing, and filtering to obtain the radix notoginseng, radix astragali and lycii fructus wine. The radix notoginseng, radix astragali and lycii fructus wine is tawny clear and transparent liquid and has the aromatic fragrance of the Chinese herbs and the wine fragrance, and two fragrances are reasonably mixed together, so that the wine is stronger and fragrant in taste. The radix notoginseng, radix astragali and lycii fructus wine has a function of improving the immunity. By strictly controlling the mass ratio of the radix notoginseng, radix astragali and lycii fructus, the synergism of the radix notoginseng, radix astragali and lycii fructus is guaranteed, the dissolution of active ingredients is promoted, and the stability of the active ingredients is mutually promoted, so that the stability of the radix notoginseng, radix astragali and lycii fructus wine is guaranteed.
ETHNOPHARMACOLOGICAL RELEVANCE: Opuntia monacantha belongs to the cactus family Cactaceae and is also known by cochineal prickly pear, Barbary fig or drooping prickly pear. It was traditionally used to treat pain and inflammation. O. monacantha cladodes showed pharmacological effects such as antioxidant potential owing to the presence of certain polysaccharides, flavonoids, and phenols.
AIM OF THE STUDY: This research aimed to evaluate the anti-inflammatory as well as the anti-arthritic potential of ethanol extract of Opuntia monacantha (E-OM).
MATERIALS AND METHODS: In vivo edema in rat paw was triggered by carrageenan and used to evaluate anti-inflammatory activity, while induction of arthritis by Complete Freund's Adjuvant (CFA) rat model was done to measure anti-arthritic potential. In silico studies of the previously High performance liquid chromatography (HPLC) characterized metabolites of ethanol extract was performed by using Discovery Studio 4.5 (Accelrys Inc., San Diego, CA, USA) within active pocket of glutaminase 1 (GLS1) (PDB code: 3VP1; 2.30 Å).
RESULTS: EOM, particularly at 750 mg/kg, caused a reduction in the paw edema significantly and decreased arthritic score by 80.58% compared to the diseased group. It revealed significant results when histopathology of ankle joint was examined at 28th day as it reduced inflammation by 18.06%, bone erosion by 15.50%, and pannus formation by 24.65% with respect to the diseased group. It restored the altered blood parameters by 7.56%, 18.47%, and 3.37% for hemoglobin (Hb), white blood count (WBC), and platelets, respectively. It also reduced rheumatoid factor RF by 13.70% with concomitant amelioration in catalase (CAT) and superoxide dismutase (SOD) levels by 19%, and 34.16%, respectively, in comparison to the diseased group. It notably decreased mRNA expression levels of COX-2, IL-6, TNF-α, IL-1, NF-κβ and augmented the levels of IL-4 and IL-10 in real time PCR with respect to the diseased group and piroxicam. HPLC analysis previously performed showed that phenolic acids and flavonoids are present in E-OM. Molecular docking studies displayed pronounced inhibitory potential of these compounds towards glutaminase 1 (GLS1), approaching and even exceeding piroxicam.
CONCLUSIONS: Thus, Opuntia monacantha could be a promising agent to manage inflammation and arthritis and could be incorporated into pharmaceuticals.
Objectives: The present study aimed to investigate the effects of a Virtual Reality cognitive training intervention (VRCTI) on cognitive function changes measured with a cognitive test battery and improvement of quality of life in older adults with cognitive impairment in long-term care facilities.

Method: Weekly 1-hour sessions were implemented over 8 weeks targeting sustained and selective attention, memory, cognitive functions, and rule deduction. The VRCTI comprised 12 different tasks distributed in 8 sessions with different difficulty levels. The passive control group received usual care. Older adults were randomly assigned to either VR or control groups. An experimental pre-post design was used. Accuracy, error, and repetition rates were measured throughout each session. Intervention effects were analyzed using a generalized estimating equation model.
The treatment effects of ORLISTAT were examined for 2 years in four of the five 1-year weight management clinical studies previously discussed (see Table 6). At the end of year 1, the patients' diets were reviewed and changed where necessary. The diet prescribed in the second year was designed to maintain patient's current weight. ORLISTAT was shown to be more effective than placebo in long-term weight control in four large, multicenter, 2-year double-blind, placebo-controlled studies.

Pooled data from four clinical studies indicate that 74% of all patients treated with 120 mg three times a day of ORLISTAT and 76% of patients treated with placebo completed 2 years of the same therapy. Pooled data from four clinical studies indicate that the mean weight loss difference between ORLISTAT 120 mg three times a day and placebo treatment groups at year 2 in those patients who completed 1 year of treatment (ITT LOCF) was 3%. In the same studies cited in the One-year Results (see Table 6), the percentages of patients achieving a ≥5% and ≥10% weight loss after 2 years are shown in Table 8.

The relative changes in risk factors associated with obesity following 2 years of therapy were also assessed in the population as a whole and the population with abnormal risk factors at randomization.

Population as a Whole

The relative differences in risk factors between treatment with ORLISTAT and placebo were similar to the results following 1 year of therapy for total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, fasting glucose, fasting insulin, diastolic blood pressure, waist circumference, and hip circumference. The relative differences between treatment groups for HDL cholesterol and systolic blood pressure were less than that observed in the year one results.

Population With Abnormal Risk Factors at Randomization

The relative differences in risk factors between treatment with ORLISTAT and placebo were similar to the results following 1 year of therapy for LDL- and HDL-cholesterol, triglycerides, fasting insulin, diastolic blood pressure, and waist circumference. The relative differences between treatment groups for LDL/HDL ratio and isolated systolic blood pressure were less than that observed in the year one results.
The spleen clears rigid erythrocytes from the circulation. Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria. By screening 13 555 compounds with spleen-mimetic microfilters, the inventors identified 82 compounds that stiffen mature gametocytes. Eight active families were identified, including known anti-malarial, antimicrobial or anticancer agents, amongst others. Hit prioritization based on accessible safety and pharmacokinetics data in humans identified 3 leading candidates. NITD609 displayed killing and stiffening effects (IC50 of 100 and 50 nM, respectively), while TD-6450 and L-THP had a pure or predominant stiffening effect (IC50 of 600 and 5 nM, respectively). These values are lower than or close to peak plasma concentrations in humans. Clinical trials with these strong malaria transmission-blocking candidates are envisioned.
Hair dye compsn. based on oxidation dyestuffs contains an alkali-stable dye indicator which is inert and not rinse-fast towards hair, and gives the compsn. a colour corresp. to that produced on oxidation. Pref. the indicators are ultramarine or phthalocyanine dyes or their mixtures. User does not have to rely on the package information as regards the desired colour and can judge the final tint by opening the package.
BACKGROUND: Preventing early aneurysm rebleeding is crucial in the management of aneurysmal subarachnoid hemorrhage (SAH). Lowering systolic blood pressure (SBP) has been proposed as a potential strategy, but the evidence remains inconclusive. This systematic review and meta-analysis aimed to determine if a specific SBP target could reduce the risk of aneurysm rebleeding prior to treatment.
METHODS: Electronic databases were systematically searched for studies comparing SBP between SAH patients with and without aneurysm rebleeding before surgical treatment. Data on SBP values, patient characteristics, and rebleeding events were extracted. Meta-analyses were performed to pool mean SBP differences and odds ratios (ORs) for rebleeding at different SBP cut-offs.
RESULTS: Ten studies were included in the systematic review. Pooled data from the included studies showed that the mean SBP was higher in the rebleeding group (mean difference 5.89, 95 % CI 1.94 to 9.85). SBP ≤160 mmHg was associated with lower rebleeding risk (OR 0.30, 95 % CI 0.14 to 0.65). However, substantial heterogeneity and limitations in study designs and definitions were noted.
CONCLUSIONS: This meta-analysis suggests that SAH patients with rebleeding may present with higher SBP. However, the findings should be interpreted cautiously due to study limitations. Future prospective studies with standardized definitions and comprehensive data collection are needed to elucidate the complex relationship between blood pressure dynamics and rebleeding risk in SAH.